Dr Reddy's vs Cipla (2026): US Generics Reset, India Growth, Valuation & Which Is Better?
The post-lenalidomide comparison · Q1 FY2027
Dr Reddy's and Cipla entered FY2027 with the same uncomfortable problem: an unusually profitable North American earnings stream was fading faster than the replacement products could fully arrive.
For Dr Reddy's, the main reset came from lenalidomide. For Cipla, the decline included lenalidomide plus lower lanreotide contribution.
That makes this comparison unusually useful because investors can see how two large Indian pharma companies are trying to rebuild earnings after the same broad US generics windfall.
Dr Reddy's is responding with India, emerging markets, Europe, complex generics and consumer health. Cipla is leaning on India, respiratory, complex inhalation products, Africa and selected metabolic-care opportunities.
Both companies had weak Q1 profit, but Dr Reddy's reset was much harsher
Dr Reddy's attributable profit fell nearly 69%; Cipla's fell approximately 39%.
Dr Reddy's revenue declined 5.6% to approximately ₹8,071 crore.
Cipla's revenue increased 2.3% to approximately ₹7,119 crore.
Dr Reddy's EBITDA margin fell to 12.5%.
Cipla's EBITDA margin fell to roughly 16.7%.
The common driver was North America.
The additional Dr Reddy's problem was a ₹240 crore provision for semaglutide API inventory and related costs.
Cipla's additional challenge was a temporary lanreotide supply problem linked to its supplier and the need for newer US launches to scale faster.
Dr Reddy's vs Cipla: current financial comparison
| Metric | Dr Reddy's | Cipla | Current Edge |
|---|---|---|---|
| Market capitalisation | ₹102,660 Cr | ₹116,132 Cr | Cipla slightly |
| P/E | 31.86x | 34.45x | Dr Reddy's |
| P/B | 2.71x | 3.37x | Dr Reddy's |
| Industry P/E | 34.89x | 34.89x | Dr Reddy's below benchmark |
| ROE | 11.75% | 11.82% | Effectively tied |
| ROCE | 14.80% | 15.67% | Cipla slightly |
| Net profit margin | 9.70% | 11.90% | Cipla |
| Debt-to-equity | 0.17 | 0.01 | Cipla |
| Interest coverage | 15.39x | 97.04x | Cipla |
| Current ratio | 1.80x | 3.44x | Cipla |
| Operating cash flow / PAT | 1.35x | 1.02x | Dr Reddy's |
| 5-year sales growth | 12.09% | 8.01% | Dr Reddy's |
| 5-year profit growth | 16.54% | 10.03% | Dr Reddy's |
| 5-year free cash flow | ₹11,253 Cr | ₹13,262 Cr | Cipla slightly |
| Dividend yield | 0.65% | 0.90% | Cipla |
| Promoter holding | 26.64% | 29.21% | Similar |
| Promoter pledge | 0% | 0% | Both |
| FII holding | 21.14% | 22.55% | Similar |
| DII holding | 30.72% | 31.71% | Similar |
| Bull Run Score | 41.0/100 | 40.2/100 | Essentially tied |
The stocks look like peers on valuation because their current problems are similar
Dr Reddy's trades at roughly 31.9x earnings and Cipla around 34.5x, both close to the current pharma-industry P/E of about 34.9x.
The difference is modest.
Dr Reddy's also trades at a lower P/B of roughly 2.71x versus Cipla at about 3.37x.
This makes Dr Reddy's statistically cheaper.
But valuation alone cannot answer the comparison because Cipla currently earns the higher margin and has the cleaner conventional balance sheet.
North America hurt both companies, but Dr Reddy's was hit harder
Dr Reddy's North America revenue fell about 35% year on year; Cipla's fell approximately 21%.
Dr Reddy's North America
Revenue was approximately ₹2,205 crore.
The decline primarily reflected lower lenalidomide contribution.
Management said the underlying base business excluding lenalidomide grew at a double-digit rate.
Six new products were launched during the quarter.
Cipla North America
Revenue was approximately ₹1,532 crore, or $162 million.
Lower lenalidomide and lanreotide contribution created the difficult comparison.
Cipla expects sequential improvement from products including generic Ventolin, nintedanib and dapagliflozin along with future pipeline launches.
The end of lenalidomide is forcing investors to judge the real base businesses
High-value limited-competition generic products can temporarily make an ordinary earnings base look exceptional.
Lenalidomide did that across several Indian generic manufacturers.
As that opportunity disappears, current margins and profit growth look dramatically weaker even when the underlying operating franchise is still expanding.
This is why simply comparing Q1 profit growth creates the wrong conclusion.
The better question is what each company can earn once the temporary US profit pool is replaced by recurring businesses.
Dr Reddy's replacement engine is geographically diversified
Dr Reddy's Q1 growth outside North America was impressive.
India revenue increased 17% to approximately ₹1,718 crore.
Emerging Markets revenue increased 31% to approximately ₹1,833 crore.
Europe contributed approximately ₹1,444 crore in the quarter.
Branded businesses comprising India, Emerging Markets and nicotine-replacement consumer health represented roughly 52% of total revenue.
This gives Dr Reddy's a credible path toward reducing North America's importance.
Cipla's replacement engine starts with India
Cipla's One India business generated a record ₹3,452 crore of Q1 revenue, up approximately 12% year on year.
That represents close to half of company revenue.
Branded prescription growth was particularly strong in respiratory, cardiac, urology and anti-diabetes therapies.
Cipla's chronic portfolio has become increasingly important to domestic growth.
This franchise is less exposed to US generic price erosion and therefore provides a useful stabiliser while North America resets.
Dr Reddy's India business is smaller but growing faster
Dr Reddy's India revenue grew 17%, compared with Cipla's approximately 12%.
Dr Reddy's management said organic India growth excluding acquisitions was about 15.5%.
The company launched seven new brands during the quarter.
It also continued building an innovation and metabolic-care portfolio.
Cipla remains larger in India, but Dr Reddy's current growth rate is higher.
Cipla has the stronger respiratory identity
Respiratory medicine is one of the clearest areas where Cipla has a differentiated competitive position.
The company has decades of expertise in inhalation therapies.
Foracort is one of its flagship Indian brands.
In North America, complex inhaled products such as generic Ventolin and future inhalation opportunities are central to rebuilding the US business.
Respiratory products are technically harder to manufacture and obtain approval for than many conventional tablets, potentially reducing the number of competitors.
Dr Reddy's complex-product strategy is broader than respiratory
Dr Reddy's is pursuing complex generics across oncology, peptides, injectables, drug-device combinations and other differentiated categories.
Its Q1 launches included bosutinib and nintedanib.
The company has also entered semaglutide markets and continues to develop biosimilars and partnered innovative therapies.
This breadth means Dr Reddy's does not depend on one therapeutic area replacing lenalidomide.
It also means execution has to work across several technically demanding programmes.
The semaglutide provision is specific to Dr Reddy's, not a generic industry problem
Dr Reddy's Q1 included a ₹240 crore provision related to semaglutide API inventory and associated supply challenges.
Management described the issue as a meaningful temporary drag on the quarter and expects supply to resume.
That means Q1's 12.5% EBITDA margin should not automatically be treated as a new permanent run rate.
However, investors should still monitor whether semaglutide manufacturing and supply execution normalises as planned.
Cipla had its own supply problem: lanreotide
Cipla's North American results were also affected by the interruption of lanreotide supply.
The company's sole supplier faced a US FDA inspection issue that temporarily disrupted production.
Because lanreotide had been an important high-value product, the interruption amplified the earnings decline already caused by the lower lenalidomide base.
Cipla's US recovery therefore depends partly on the launch pipeline and partly on restoring normal contribution from affected complex products.
Cipla currently has the better reported margin profile
Bull Run's current net profit margin is approximately 11.9% for Cipla and 9.7% for Dr Reddy's.
Q1 EBITDA margin also favoured Cipla: about 16.7% versus 12.5% for Dr Reddy's.
Both were sharply below prior-year levels because of the North American reset.
The key test over the next several quarters will be how quickly margins recover as newer products scale.
ROE is almost identical
There is virtually no difference in current ROE.
Cipla's ROE is approximately 11.82%.
Dr Reddy's is approximately 11.75%.
ROCE gives Cipla a modest advantage at about 15.67%, compared with Dr Reddy's around 14.80%.
That makes this a much closer capital-efficiency contest than the Sun Pharma comparisons.
Cipla has the cleaner conventional balance sheet
Cipla's debt-to-equity is effectively zero at approximately 0.01.
Its interest coverage is around 97x.
Its current ratio is approximately 3.44x.
Cipla also reported a Q1 FY2027 net cash position of approximately ₹9,494 crore.
Dr Reddy's debt-to-equity is approximately 0.17, with interest coverage near 15.4x and current ratio around 1.80x.
Dr Reddy's nevertheless also had net cash, reporting a net cash surplus of approximately ₹3,057 crore at June 30, 2026.
Cipla has the stronger liquidity cushion today.
Dr Reddy's currently converts profit into operating cash better
Dr Reddy's operating-cash-flow-to-net-profit ratio is approximately 1.35x, versus Cipla at around 1.02x.
Cipla has the slightly larger five-year free-cash-flow figure in Bull Run's database: approximately ₹13,262 crore versus Dr Reddy's ₹11,253 crore.
These numbers point in different directions because one measures current conversion and the other cumulative free cash flow.
Both businesses have demonstrated the ability to generate cash rather than merely report accounting earnings.
Dr Reddy's has grown faster over five years
Five-year sales growth is approximately 12.1% for Dr Reddy's and 8.0% for Cipla.
Dr Reddy's five-year profit growth is about 16.5%.
Cipla's is approximately 10.0%.
That historical growth advantage is one of the strongest arguments in favour of Dr Reddy's current lower valuation.
However, investors should not rely on Dr Reddy's raw automated five-year EPS CAGR without checking split adjustment because the company completed a 1:5 share split in October 2024.
Emerging markets give Dr Reddy's another growth route
Dr Reddy's Emerging Markets business grew 31% in Q1 FY2027.
Cipla also has substantial Africa and emerging-market exposure.
Cipla's One Africa business grew approximately 12%, while Emerging Markets and Europe revenue rose approximately 16% in rupee terms during Q1.
Both companies are therefore diversifying beyond India and North America.
Dr Reddy's current emerging-market growth rate is stronger.
Cipla's Africa business remains strategically important
Cipla has a long-standing South African presence and a meaningful regional pharmaceutical platform.
Africa diversifies the company away from the US while supporting branded and prescription-product growth.
The company has maintained strong positions in South Africa and other African markets.
This exposure is less prominent in Indian investor discussions than North America, but it contributes materially to Cipla's geographic resilience.
The current valuation slightly favours Dr Reddy's
Dr Reddy's trades below Cipla on both P/E and P/B.
Its P/E is approximately 31.86x compared with Cipla at 34.45x.
Its P/B is about 2.71x compared with Cipla at 3.37x.
Dr Reddy's also has the faster five-year growth record.
Cipla's valuation premium can be partly justified by stronger current margins, liquidity and respiratory franchise quality.
This is not a large valuation gap, which means operational execution will matter more than multiple differences.
Market performance has not produced a decisive winner
| Market Metric | Dr Reddy's | Cipla |
|---|---|---|
| Price on 25 Aug 2026 | ₹1,193.50 | ₹1,422 |
| 1-month return | +3.63% | +0.81% |
| 3-month return | -9.51% | +0.27% |
| 6-month return | -9.54% | +4.71% |
| 1-year return | -7.04% | -11.19% |
| 52-week high | ₹1,414.90 | ₹1,673 |
| 52-week low | ₹1,101 | ₹1,170 |
| RSI (14) | 65.35 | 26.76 |
Dr Reddy's has recently rebounded, reflected in its higher RSI.
Cipla is technically much weaker over the short term, with RSI below 30 in Bull Run's current snapshot.
That does not mean Cipla is fundamentally cheaper. Its trailing P/E remains above Dr Reddy's despite weaker recent price momentum.
Dr Reddy's: what needs to work from here
Replacement revenue
- Complex US launches.
- India growth.
- Emerging Markets growth.
- NRT consumer health.
- European portfolio expansion.
Potential advantages
- Lower P/E.
- Lower P/B.
- Faster five-year sales growth.
- Faster five-year profit growth.
- Strong operating cash conversion.
Main risks
- US earnings reset.
- Semaglutide supply execution.
- Lower current margin.
- Complex launch risk.
- Regulatory observations at manufacturing facilities.
Cipla: what needs to work from here
Replacement revenue
- Respiratory launches.
- India chronic growth.
- Lanreotide recovery.
- Africa.
- Emerging Markets and Europe.
Potential advantages
- Strong respiratory expertise.
- Record India revenue.
- Higher current margin.
- Very strong liquidity.
- Net cash above ₹9,000 crore.
Main risks
- US legacy-product decline.
- Lanreotide supplier disruption.
- New pipeline needs to scale.
- Five-year growth trails Dr Reddy's.
- Current P/E is slightly higher.
Dr Reddy's vs Cipla: which wins each category?
Market capitalisation: Cipla slightly.
P/E valuation: Dr Reddy's.
P/B valuation: Dr Reddy's.
ROE: Essentially tied.
ROCE: Cipla slightly.
Net profit margin: Cipla.
Five-year sales growth: Dr Reddy's.
Five-year profit growth: Dr Reddy's.
Current operating cash conversion: Dr Reddy's.
Five-year free cash flow: Cipla slightly.
Balance-sheet liquidity: Cipla.
India revenue scale: Cipla.
Current India growth rate: Dr Reddy's.
Respiratory franchise: Cipla.
Current Emerging Markets momentum: Dr Reddy's.
Bull Run Score: Essentially tied.
Dr Reddy's vs Cipla FAQs
Which stock is cheaper?
Dr Reddy's on both trailing P/E and price-to-book.
Which has higher ROE?
The difference is negligible. Cipla is approximately 11.82% and Dr Reddy's around 11.75%.
Which has higher ROCE?
Cipla slightly, at approximately 15.67% versus Dr Reddy's at about 14.80%.
Which company has stronger five-year sales growth?
Dr Reddy's, at approximately 12.1% versus Cipla around 8.0%.
Why did Dr Reddy's North America business fall?
The primary reason was the decline in lenalidomide revenue after an unusually profitable prior period.
Why did Cipla's North America revenue fall?
Lower lenalidomide and lanreotide contribution created a difficult year-on-year comparison.
Which is stronger in India?
Cipla has the larger current India revenue base. Dr Reddy's grew India revenue faster in Q1 FY2027.
Which has the stronger balance sheet?
Cipla currently has stronger conventional liquidity and a larger net cash position.
Research sources
- Bull Run current fundamental, ownership and technical data
- Bull Run Smart Screeners
- Dr Reddy's investor centre
- Dr Reddy's Q1 FY2027 earnings call transcript
- Dr Reddy's Q1 FY2027 regulatory earnings release
- Dr Reddy's North America and global generics business
- Cipla official website and investor centre
- Cipla FY2026 annual report
- Cipla FY2026 investor presentation
Disclaimer
This comparison is educational and informational only. Pharmaceutical results can be affected by limited-period generic opportunities, supply interruptions, regulatory inspections, product launches, price erosion, currency movements and R&D outcomes. Dr Reddy's completed a 1:5 stock split in 2024, so automated long-term per-share growth fields require adjustment. Financial metrics, ownership and market prices change over time. Nothing here recommends buying, selling or holding Dr Reddy's, Cipla or any other security. Bull Run is not a SEBI-registered Research Analyst or Investment Adviser.